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Opioidergic system involves in regulation of sleep and wakefulness. It is possible, therefore, that genetic 
polymorphisms in OPRM1 influence sleep quality. This study investigated the association of OPRM1 
polymorphisms with subjective sleep quality among opioid-naive individuals. This cross-sectional 
observational study involved 161 opioid-naive males (mean age = 27.74 years; range: 18−63 years). 
Subjective sleep quality was assessed with the translated and validated Malay version of the Pittsburgh 
Sleep Quality Index (PSQI). DNA was extracted from whole blood and subjected to polymerase chain 
reaction (PCR)-genotyping for two OPRM1 polymorphisms (118A>G and IVS2+691G>C). Subjects 
with combined 118A and IVS2+691G alleles (AC haplotype) had significantly lower PSQI scores [mean 
(SD) = 4.29 (1.76)] compared to those without the haplotype [4.99 (2.50)] (p = 0.004). On the other 
hand, subjects with combined heterozygous genotype (GC/AG diplotype) had significantly higher PSQI 
scores compared to those without the diplotype [6.04 (2.48) vs 4.54 (2.22), p = 0.004]. In opioid-naive 
individuals, AC haplotype and GC/AG diplotype for the 118A>G and IVS2+691G>C polymorphisms 
of OPRM1 are associated with better and poorer sleep quality, respectively.
Keywords: Sleep-Wake Transition Disorders. Sleep quality. Sleep/genetic. Polymorphism. Pittsburgh 
Sleep Quality Index. OPRM1. Opioid receptors /µ analysis. 
INTRODUCTION
Poor sleep quality has been reported in general 
population. In German, 36% of the general population 
slept badly (Hinz et al., 2017). A survey conducted in 
China reported that the overall prevalence of insomnia was 
26.6% among 26,851 subjects from the general population 
(Tang et al., 2017). A study among 794 medical students 
in Malaysia found that 16.1% reported bad sleep quality 
(Zailinawati et al., 2009). In another study, a higher 
prevalence of poor sleep quality (32.9%) was reported 
among 1,118 Malaysian tertiary students (Lai, Say, 2013). 
Shift work, sleep disorders, socioeconomic status, aging, 
anxiety and the number of chronic disease, amongst others, 
were found to be significantly associated with poor sleep 
quality (Guo et al., 2013; Patel et al., 2010; Luo et al., 
2013; Hinz et al., 2017; Tang et al., 2017). Poor sleep 
quality is often associated with accidents (Garbarino et 
al., 2001; Powell et al., 2007), and an increased in total 
healthcare and lost productivity costs (Sarsour et al., 
2011). In addition, sleep problems are associated with 
a decreased in health related quality of life (Schubert et 
al., 2002; Rashid et al., 2012) and have been reported 
as a risk factor for all-cause mortality (Marshall et al., 
2008). More recently, a community-based population 
study has shown that moderate-to-severe sleep apnea is 
independently associated with a large increased risk of 
all-cause mortality, incident stroke, and cancer incidence 
and mortality (Marshall et al., 2014).
Genetic and environmental factors have been 
implicated in sleep and sleep problems (Heath et al., 
1990; Lessov-Schlaggar et al., 2008; Watson et al., 2006; 
Genderson et al., 2013). Research suggests that genetic 
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differences accounted for at least 33% of the variance 
in sleep quality and sleep disturbance and 40% of the 
variance in sleep pattern (Heath et al., 1990). Recently, a 
twin research has highlighted the importance of genes on 
the Pittsburgh Sleep Quality Index (PSQI) and the seven 
components of the PSQI (Genderson et al., 2013). Genetic 
association studies have provided some progress in 
understanding the genetic control of sleep and heritability 
of sleep disorders (Varvarigou et al., 2011; Evans et al., 
2013; Palagini, Biber, Riemann, 2014; Wisor, Kilduff, 
2005; Millstein et al., 2011; Andretic, Franken, Tafti, 
2008). Individual differences in regulation of sleep and 
wakefulness can be explained by variation within specific 
genes, and single nucleotide polymorphisms (SNPs) or 
combinations of SNP alleles that tend to be inherited 
together (haplotypes) may be associated with sleep in 
healthy populations and among sleep-disordered patients 
(Andretic, Franken, Tafti, 2008).
The endogenous opioid peptide β-endorphin is 
known to be involved in the regulation of sleep and 
wakefulness (King et al., 1981). Pharmacological 
studies have shown that the naturally-occurring opioid 
peptide, β-endorphin, interacts preferentially with opioid 
receptor, mu 1 (OPRM1). A previous study has shown 
that β-endorphin and morphine injected intraventricularly 
produced insomnia in cats (King et al., 1981). Their 
findings showed that deep slow wave sleep (SWS) was 
sharply inhibited, rapid eye movement (REM) sleep was 
entirely suppressed, and light slow wave sleep, occurring 
in brief, isolated episodes, became the most abundant 
stage of sleep. They also found that an opioid receptor 
antagonist, naloxone, injected subcutaneously reversed the 
effects of β-endorphin and morphine on the two stages of 
SWS, but it did not counteract the REM-suppressant effect 
of either β-endorphin or morphine (King et al., 1981). 
This data may indicate an involvement of an inner opioid 
in the regulation of sleep-wake cycle (King et al., 1981), 
and further research suggest the existence of somnogenic 
effect of opioidergic system in the caudal nucleus tractus 
solitarius (NTS) (Reinoso-Barbero, Andrés, 1995). 
Later, electroacupuncture (EA) of Anmian acupoints 
has been shown to increase non-rapid eye movement 
(NREM) sleep, but not REM sleep, during the dark 
period in rats (Cheng et al., 2011). This data suggest 
that stimulation of the opiodergic neurons to increase 
the concentrations of β-endorphin and the involvement 
of the μ-opioid receptors may also be a mechanism by 
which acupuncture affects sleep (Cheng et al., 2011). It is 
possible, therefore, some of the OPRM1 polymorphisms 
that affect the density and function, and consequently the 
signaling efficacy of μ-opioid receptors may contribute to 
inter-individual variations in the sleep quality. The most 
frequently studied polymorphism of OPRM1, 118A>G 
(dbSNP rs1799971, Asn40Asp) polymorphism, is found in 
exon 1. It may affect the μ-opioid receptor N-glycosylation 
and reduced stability of the receptor (Huang et al., 2012). 
IVS2+691G>C (dbSNP rs2075572) polymorphism is 
found within intron 2 at 691 bp downstream of exon 2 
(Xin, Wang, 2002; Hoehe et al., 2000; Lötsch, Geisslinger, 
2006). It may change the regulation of the expression of 
OPRM1 gene and may also cause formation of different 
isoforms of human μ-opioid receptor (Hoehe et al., 2000; 
Wendel, Hoehe, 1998). Unfortunately, the association 
between OPRM1 polymorphisms and sleep quality 
is unknown and requires exploration. Examining the 
influence of genetic polymorphisms on sleep quality will 
be informative in terms of gaining a deeper understanding 
of sleep and sleep problems. In this study, we aimed to 
investigate the influence of OPRM1 polymorphisms on 
sleep quality among opioid-naive individuals.
MATERIAL AND METHODS
Participants
One hundred and sixty one healthy volunteers who 
had taken part in a pharmacogenetics study conducted 
by the Institute for Research in Molecular Medicine 
(INFORMM), USM, Kota Bharu, Kelantan, and who 
satisfied inclusion and exclusion criteria were recruited 
from the local community between March and October 
2013. Opioid-naive individual was defined as individual 
who have not taken any opioids including morphine and 
methadone to the best of their knowledge and have had 
two consecutive negative urine screenings results for 
illicit drugs. Inclusion criteria were: 1) Malay male aged 
more than 18 years; 2) Free of acute medical, surgical and 
psychiatric illness; and 3) Free of regular use of alcohol. 
The exclusion criteria were: 1) individuals who were 
currently taking illicit benzodiazepines, cannabinoids and 
barbiturates; 2) individuals on regular anticonvulsants, 
neuroleptics or analgesics; 3) individuals with chronic 
or ongoing acute pain; 4) individuals with a history of 
analgesics ingestion within three days before the study; 
and 5) individuals with severe cognitive impairment 
which may interfere with sleep assessments and/or 
communication.
Written informed consent was obtained from each 
subject after a complete description of the study. The study 
was registered with the National Institutes of Health (NIH) 
of the Ministry of Health (MOH), Malaysia (available at 
www.nmrr.gov.my, National Medical Research Register 
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(NMRR) number: NMRR-13-524-16614). The study was 
evaluated and approved by the Human Research Ethics 
Committee (HREC), Universiti Sains Malaysia (USM) 
in Kelantan, Malaysia (Reference number: USMKK/PPP/
JEPeM (253.3 [14]).
Assessment of subjective sleep quality using the 
Malay version of the Pittsburgh Sleep Quality 
Index (PSQI-M)
Subjective sleep quality was measured by the 
Malay version of the Pittsburgh Sleep Quality Index 
(PSQI–M) (Buysse et al., 1989). The PSQI is a validated 
questionnaire to measure subjective sleep quality and 
disturbances during the previous month that has been 
translated into several languages including Malay. The 
Malay translation of this questionnaire was performed by 
MAPI Research Trust and permission for use the Malay 
version of the Pittsburgh Sleep Quality Index – PSQI was 
obtained from the author at the University of Pittsburgh 
(Buysse et al., 1989). The PSQI contains 19 items that 
are included in scoring. The 19 individual items are used 
to generate seven component scores: subjective sleep 
quality, sleep latency, sleep duration, habitual sleep 
efficiency, sleep disturbances, use of sleep medications, 
and daytime dysfunction. Each of the seven component 
scores is determined based on scoring guidelines, with 
the seven component scores each with a potential range 
of 0–3, where ‘3’ reflects the negative extreme on the 
Likert Scale. The sum of these seven component scores 
yields one global score of subjective sleep quality with 
a potential range of 0–21, with higher scores represent 
poorer subjective sleep quality (i.e. a global PSQI score 
of > 5 is associated with poor sleep quality) (Buysse et 
al., 1989). 
Genotyping methods for detection of OPRM1 
polymorphisms
Subjects provided 5 mL venous blood sample, and 
genomic DNA was extracted from 200 µl of whole blood 
by use of the QIAamp DNA Blood Mini Kit (Qiagen 
Gmbh, Hilden, Germany). Allele-specific multiplex 
polymerase chain reaction (PCR) was used to detect 
OPRM1 polymorphisms [118A>G (dbSNP rs1799971) 
and IVS2+691G>C (dbSNP rs2075572)] (Mohamed 
Nazar, 2013; Zahari et al., 2015; Zahari et al., 2016b, 
Zahari et al., 2016a). All reactions were performed on 
the Applied Biosystems Veriti 96-Well Thermal Cycler 
(Applied Biosystems, USA). A complete PCR method is 
available upon request.
Statistical analysis
Sample size was calculated prior the start of the 
study based on the Cohen sample size table (Cohen, 1992), 
using medium population effect size (ES) of 0.50 assuming 
a two-tailed 5% type I error rate and 80% power. The 
required sample size per group was 64 alleles or subjects 
for comparisons of means of two groups (under allelic 
additive model, genotype dominant and recessive model). 
OPRM1 haplotypes and diplotypes were constructed based 
on the expectation-maximization (EM) algorithm using 
the population genetic data analytical program, Golden 
Helix SNP and Variation Suite 7 (SVS 7, version 7.3.1; 
Golden Helix Inc., Bozeman, MT, USA). The sum of seven 
component scores of the PSQI was calculated as the global 
score for subjective sleep quality. Means and standard 
deviations were calculated for the global score of the 
PSQI. Independent t-test and one-way ANOVA test were 
used to compare the mean global PSQI scores between 
OPRM1 polymorphisms (118A>G and IVS2+691G>C) 
according to their genotypes and allelic additive models, 
genotype dominant and recessive models, haplotypes and 
diplotypes where appropriate. Haplotypes and diplotypes 
with frequencies less than 10% were pooled, since rare or 
minor haplotypes and diplotypes provide little additional 
information while increasing the degrees of freedom. Data 
analyses were done after all genotyping of the subjects was 
completed. There were no missing data for all the subjects 
included in this study. Given the exploratory nature of this 
study and only one gene was tested (Belfer et al., 2013), 
correction for multiple testing was not performed for the 
exploratory statistical analyses. Statistical analysis was 
carried out using SPSS/Win software (Version 22, SPSS, 
Inc., Chicago, IL, USA). A p value < 0.05 was considered 
significant.
RESULTS
Descriptive statistics
A total of 161 opioid-naive individuals fulfilled 
inclusion and exclusion criteria, gave informed consent and 
completed the study. The mean age of study participants 
was 27.74 years [standard deviation (SD) = 10.32; range: 
18−63 years]. The mean body mass index (BMI) was 
24.82 kg/m2 (SD = 5.33; range: 15−45 kg/m2). The mean 
PSQI score was 4.76 (SD = 2.31, range 0–13), slightly 
below a cut-off score of 5, thus indicating good overall 
sleep quality (Buysse et al., 1989). Specifically, 68.9% 
(N = 111) had PSQI scores of ≤ 5, indicating they were 
‘good sleepers’.
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OPRM1 polymorphisms
The 118A/G and IVS2+691G/C alleles of OPRM1 
were successfully amplified from the DNA of 161 
opioid-naive subjects. The allele frequencies for 118G 
and IVS2+691C were 53.1% and 85.1%, respectively. 
The combination of the individual polymorphisms into 
OPRM1 haplotype pairs revealed the presence of 7 
diplotypes. The most common haplotype pair was AC/GC 
(N = 54, 33.5%), followed by GC/GC (N = 45, 28.0%), 
GC/AG (N = 23, 14.3%), and AC/AG (N = 21, 13.0%). 
Association of OPRM1 polymorphisms with PSQI 
scores
Table I shows that subjects with homozygous 118 
AA genotype had lower PSQI scores compared to those 
without 118 AA genotype (118 AG/GG genotype) (4.30 
vs 4.90), but the difference was not statistically significant 
(p = 0.167). 
Subjects with the heterozygous IVS2+691 GC 
genotype had the highest PSQI scores among the three 
IVS2+691G>C genotypes (Table I). Subjects with the 
IVS2+691G allele (IVS2+691 GG/GC genotype) had 
higher PSQI scores compared to those without the allele 
(IVS2+691 CC genotype) (5.26 vs 4.55), but the difference 
again did not reach statistical significance (p = 0.079). 
In view of this, we performed haplotype and 
diplotype analysis constructed from the two OPRM1 
polymorphisms. Haplotype analysis revealed a significant 
difference of the mean PSQI scores between subjects 
with AC haplotype and those without this haplotype 
TABLE I - Association between 118A>G and IVS2+691G>C polymorphisms and PSQI scores in opioid-naive Malay Males
Polymorphism N (%) Mean SD Test statistic (df) p valuec
118A>G
Genotype (N = 161)
AA 37 23.0 4.30 1.61 1.11 (2, 158)a 0.331
AG 77 47.8 4.81 2.22
GG 47 29.2 5.04 2.84
Allele (N = 322)
A 151 46.9 4.56 1.95 -1.50 (313)b 0.134
G 171 53.1 4.94 2.57
Dominant model
AA 37 23.0 4.30 1.61 -1.39 (159)b 0.167
AG + GG 124 77.0 4.90 2.47
Recessive model
AA + AG 114 70.8 4.64 2.05 -0.88 (67)b 0.382
GG 47 29.2 5.04 2.84
IVS2+691G>C
Genotype (N = 161)
GG 1 0.6 4.00 - 1.71 (2, 158)a 0.184
GC 46 28.6 5.28 2.34
CC 114 70.8 4.55 2.28
Allele (N = 322)
G 48 14.9 5.23 2.31 1.54 (320)b 0.124
C 274 85.1 4.68 2.30
Dominant model
GG 1 0.6 4.00 - -0.33 (159)b 0.743
GC + CC 160 99.4 4.76 2.31
Recessive model
GG + GC 47 29.2 5.26 2.33 1.77 (159)b 0.079
CC 114 70.8 4.55 2.28
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[t (278) = -2.90, p = 0.004]. Subjects with the AC 
haplotype had significantly lower PSQI scores compared 
to those without the haplotype (4.29 vs 4.99). 
There was also a significant difference of the 
mean PSQI scores between subjects with the combined 
heterozygous genotype (GC/AG diplotype) and those 
without this diplotype (p = 0.004). Subjects with the 
GC/AG diplotype had significantly higher PSQI scores 
compared to those without the diplotype (6.04 vs 4.54).
DISCUSSION
The present study aimed to investigate the 
associations between OPRM1 polymorphisms and sleep 
quality in opioid-naive population. This study revealed that 
the mean PSQI scores was significantly lower in carriers of 
the AC haplotype than those without the haplotype. On the 
other hand, this study found that the mean PSQI scores was 
significantly higher in carriers of the GC/AG diplotype 
than those without the diplotype. From these data, it is 
suggested that variations in OPRM1 may influence sleep 
quality even in the opioid-naive population. Previous 
research using the classical twin design has highlighted 
the contribution of genes to subjective sleep quality 
(Genderson et al., 2013). Sleep quality was measured 
using the PSQI in 1218 middle-aged twin men from the 
Polymorphism N (%) Mean SD Test statistic (df) p valuec
Haplotype (N = 322)d
GC 169 52.5 4.92 2.55 2.66 (3, 318)a 0.048
AC 105 32.6 4.29 1.76
AG 46 14.3 5.17 2.22
GG 2 0.6 6.50 4.95
GC 169 52.5 4.92 2.55 3.68 (2, 319)a 0.026
AC 105 32.6 4.29 1.76
Combined AG and GG 48 14.9 5.23 2.31
GC 169 52.5 4.92 2.55 1.32 (313)b 0.187
Not GC 153 47.5 4.58 1.99
AC 105 32.6 4.29 1.76 -2.90 (278)b 0.004
Not AC 217 67.4 4.99 2.50
AG 46 14.3 5.17 2.22 1.33 (320)b 0.186
Not AG 276 85.7 4.69 2.31
Diplotype (N = 161)
AC/GC 54 33.5 4.28 1.89 2.83 (4, 156)a 0.027
GC/GC 45 28.0 4.98 2.79
GC/AG 23 14.3 6.04 2.48
AC/AG 21 13.0 4.33 1.62
Otherse 18 11.2 4.50 2.09
AC/GC 54 33.5 4.28 1.89 -1.89 (159)b 0.061
Not AC/GC 107 66.5 5.00 2.46
GC/GC 45 28.0 4.98 2.79 0.66 (64)b 0.509
Not GC/GC 116 72.0 4.67 2.10
GC/AG 23 14.3 6.04 2.48 2.96 (159)b 0.004
Not GC/AG 138 85.7 4.54 2.22
AC/AG 21 13.0 4.33 1.62 -0.90 (159)b 0.368
Not AC/AG 140 87.0 4.82 2.39
N, number of subject/allele/haplotype/diplotype; SD, standard deviation. a F-statistic using one-way ANOVA test; b t-statistic using 
independent t-test; c p value is significant at < 0.05; d Haplotype patterns were constructed from the two OPRM1 polymorphisms 
(118A>G and IVS2+691G>C); e Diplotype with frequency less than 10.0% was pooled under ‘others’ (included AG/GG and GC/GG)
TABLE I - Association between 118A>G and IVS2+691G>C polymorphisms and PSQI scores in opioid-naive Malay Males (cont.)
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Vietnam Era Twin Study of Aging (VETSA) (mean age 
= 55.4 years; range: 51–60). They found that 34% of 
variability in the global PSQI score was due to additive 
genetic effects (heritability). Similarly, the heritability 
of poor sleep (i.e. a dichotomous measure based on the 
cut-off of global PSQI > 5) was 31%. Previous molecular 
genetic studies have begun to identify genetic variations 
related to sleep–wake behavior includes 3111 T/C SNP 
(rs1801260) of the Circadian Locomotor Output Cycles 
Kaput (CLOCK) gene (Benedetti et al., 2007) and 
variable-number tandem-repeat (VNTR) polymorphism 
of the period circadian clock 3 gene (PER3) (Viola et al., 
2007). Also, there are a number of recent genome-wide 
association analyses (GWAS) studies on sleep quality 
and quantity (Lane et al., 2017; Jones et al., 2016; Byrne 
et al., 2013).
Among the identified polymorphisms within 
the OPRM1 gene, 118A>G polymorphism is the most 
frequently studied in the literatures. An in vitro study has 
demonstrated that the 118G allele altered the β-endorphin 
binding affinity (Bond et al., 1998). The 118G allele showed 
a 3-fold increase in β-endorphin binding at the receptor 
than the most common allelic form of the receptor (Bond 
et al., 1998). β-endorphin involves in the regulation of 
sleep and wakefulness, and administration of β-endorphin 
has been shown to produce insomnia (King et al., 1981). It 
is possible, therefore, the 118G allele carriers have higher 
β-endorphin binding at the OPRM1 and consequently, 
resulted in poorer sleep quality compared to those without 
the allele. In our study, although results did not reach 
statistical significance, 118G allele carriers (118 AG/GG 
genotype) had higher PSQI scores when compared with the 
118G allele non-carriers (118 AA genotype). 
A more  s ign i f i can t  in f luence  o f  OPRM1 
polymorphisms on sleep quality was observed under 
haplotype and diplotype analysis. We found that subjects 
with AC haplotype (i.e. carriers of combined 118A and 
IVS2+691G alleles) had 14% significantly lower PSQI 
scores compared to non-carriers of this haplotype. We also 
found that subjects with GC/AG diplotype (i.e. carriers of 
combined 118 AG and IVS2+691 GC genotypes) had 33% 
significantly higher PSQI scores compared to non-carriers 
of this diplotype. Unfortunately, the exact molecular 
mechanism regarding the effects of AC haplotype and GC/
AG diplotype on the sleep quality cannot be determined 
from the current study. To the best of our knowledge, data 
on the influence of the OPRM1 haplotype and diplotype 
on sleep quality among opioid-naive individuals is not 
available for reference. However, previous studies have 
indicated that the function of the OPRM1 is under the 
influence OPRM1 polymorphisms (Xin, Wang, 2002; 
Hoehe et al., 2000; Lötsch, Geisslinger, 2006). Based on 
our results, we suggest that the AC haplotype and GC/
AG diplotype may affect OPRM1 expression or function 
(or both), and resulted in altered binding affinity between 
endogenous opioid peptides and the OPRM1, and hence 
haplotype and diplotype differences may contribute to 
inter-individual differences in sleep-wakefulness effects 
of endogenous opioid peptide β-endorphin. 
It has been previously demonstrated that the AC/
AG diplotype for the 118A>G and IVS2+691G>C 
polymorphisms of OPRM1 is associated with better 
sleep quality among opioid-dependent patients on 
MMT (Zahari et al., 2016a). However, in opioid-naive 
individuals, no significant difference of the mean PSQI 
scores was observed between subjects with the AC/AG 
diplotype and those without this diplotype (p = 0.368). It 
is highly possible that the OPRM1 affects sleep by acting 
on different mechanisms in opioid-naive individuals and 
opioid-dependent patients (Wang et al., 2012; García-
García, Drucker-Colín, 1999). At this juncture, it is 
difficult to explain the differential effects on sleep quality 
among opioid-naive individuals and opioid-dependent 
patients with these polymorphisms and further studies 
are needed.
The findings of the present study have therapeutic 
implications. The main findings here were that the 
contribution of OPRM1 polymorphisms influences to 
the sleep quality among opioid-naive individuals varied 
between genotype, haplotype and diplotype analysis. 
Most notably that subjects with GC/AG diplotype (N = 23, 
14.3%) had the PSQI scores of > 5, indicating they were 
‘poor sleepers’, and their PSQI scores was significantly 
higher than those without the diplotype. These results 
provide an initial prediction on sleep quality for individuals 
with GC/AG diplotype which enables prescription of sleep 
medications for individuals with the diplotype. Furthermore, 
the clinician may use genotyping results of OPRM1 in 
making decision about pharmacotherapeutic strategies in 
terms of the choice of medications to be prescribed, and 
dose and/or route of administration of drugs for treatment of 
postoperative sleep disturbance among patients undergoing 
surgery. Indeed, this study demonstrated that individuals 
with GC/AG diplotype are more susceptible to poor 
sleep compared to individuals without the diplotype. It is 
possible that the good sleep is more difficult to be achieved 
in individuals with GC/AG diplotype. Thus, the results of 
the current study provide new information regarding the 
genetic factors that may be consider when establishing 
clinical recommendations or a suitable treatment protocol 
for providing sleep disorder treatment and management. 
However, separate analysis of individual components of the 
Sleep quality and OPRM1 polymorphisms: a cross-sectional study among opioid-naive individuals
Braz. J. Pharm. Sci. 2018;54(1):e17217 Page 7 / 9
PSQI showed that only sleep disturbance was significantly 
associated with GC/AG diplotype [t (df) = 2.14 (26.8), p = 
0.042]. Individuals with GC/AG diplotype had 25% higher 
sleep disturbance score compared to individuals without the 
diplotype (1.35 vs 1.08). Early detection and intervention 
of sleep disturbances can help reduce the morbidity and 
mortality associated with this and helps increase patient’s 
quality of life.
Certain limitations of this study must be recognized. 
This study did not use an objective sleep evaluation test 
such as polysomnography (PSG) and did not obtain data 
on serum concentrations of β-endorphin and supporting 
data on the functional effects of OPRM1 polymorphisms 
(118A>G and IVS2+691G>C), haplotypes or diplotypes 
on OPRM1 expression or function (or both). Only males 
were included but we aimed to reduce the confounding 
effects of gender on sleep quality (Fatima et al., 2016). 
In view that correction for multiple comparisons was not 
performed for exploratory statistical analyses, caution 
is required when reviewing these analyses. The sample 
size was another limitation, but we considered our study 
as more explorative in nature and replication by other 
investigators and further studies with larger sample 
sizes are encouraged. This study lacked a multivariate 
approach. Non-genetics sleep-related factors were not 
reported, and this study was design to exclude subjects 
with chronic medical and psychiatric illness such as 
chronic pain, depression and anxiety that are associated 
with sleep disorder because our focus was to look into 
pharmacogenetics factors associated with sleep quality 
among opioid-naive individuals. However, we did not find 
any significant differences between individuals with GC/
AG diplotype and those without the diplotype in terms 
of age and BMI, therefore they were well matched with 
respect to age and BMI.
Further studies are needed to study other OPRM1 
polymorphisms and genetic variations of other sleep 
related-genes, and to obtain data on endogenous 
β-endorphin concentration and data on the functional 
effects of AC haplotype and GC/AG diplotype on OPRM1 
expression and/or function.
In summary, our study indicates that the AC 
haplotype and GC/AG diplotype for the 118A>G and 
IVS2+691G>C polymorphisms of OPRM1 are associated 
with better and poorer sleep quality, respectively among 
opioid-naive individuals. Our study may be considered 
explorative in nature and it would require replication by 
other investigators. Nevertheless, these results provide 
a starting point for a better understanding of genetic 
contributions to sleep quality which may help to improve 
diagnosis and treatment of sleep disturbance.
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